I am a
Home I AM A Search Login

Osthole relieves skin damage and inhibits chronic itch through modulation of Akt/ZO-3 pathway in atopic dermatitis.

Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin condition and significantly reduces quality of life. Tight junction (TJ), which is located directly beneath the stratum corneum, maintains skin […]

Learn More >

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.

Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα-interleukin-13Rα1 heterodimer receptor signaling complex.

Learn More >

Treatment Strategies for Chronic Pruritus and Eczema/Dermatitis in Older Adults Under the Category of Chronic Eczematous Eruptions of Aging (CEEA).

Chronic eczematous eruptions of aging (CEEA) refers to a heterogenous group of longstanding, pruritic eczematous dermatoses with an unidentified etiology, or those which do not meet strict disease criteria. The […]

Learn More >

Associations Between Shower and Moisturizing Practices with Atopic Dermatitis Severity: A Prospective Longitudinal Cohort Study.

Evidence-based recommendations for optimal showering/bathing practices are lacking for atopic dermatitis (AD) patients. To determine longitudinal associations between showering/bathing practices and AD severity in AD patients. A prospective single-center dermatology […]

Learn More >

Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient Survey.

Atopic dermatitis (AD) affects 2%-10% of adults worldwide. Occurrence and severity of symptoms and treatment success vary among patients. To determine disease severity, burden, and treatment use and satisfaction in […]

Learn More >

A Mouse Model of MC903-Induced Atopic Dermatitis.

Atopic dermatitis (AD) is a chronic, relapsing, and extremely pruritic inflammatory skin disease with a particular impact on children. AD pathogenesis is not yet fully understood, and there is no […]

Learn More >

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial.

Hidradenitis suppurativa (HS) is a chronic, immune-mediated skin condition characterized by inflammatory lesions that can cause pain, impaired physical activity, and reduced quality of life. This study evaluated the efficacy […]

Learn More >

Odevixibat: A Review of a Bioactive Compound for the Treatment of Pruritus Approved by the FDA.

Odevixibat is synthesized through chemical modification of Benzothiazepine’s structure. It is a tiny chemical that inhibits the ileal bile acid transporter and is used to treat a variety of cholestatic […]

Learn More >

Cutaneous manifestations associated with immune checkpoint inhibitors.

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block key mediators of tumor-mediated immune evasion. The frequency of its use has increased rapidly and has extended to numerous cancers. ICIs […]

Learn More >

The relationship between atopic dermatitis and atopic itch in children and the psychosocial functioning of their mothers: A cross-sectional study.

Atopic dermatitis is a chronic inflammatory skin disease significantly affecting patients’ and their parents’ lives. Mothers are mostly responsible for the long-term treatment and their wellbeing is essential. The major […]

Learn More >

Search